New Phase II study showed trastuzumab-DM1 shrank tumours in women with highly advanced HER2-positive breast cancer
T-DM1, an Investigational Antibody-Drug Conjugate, Showed Encouraging Results in Women Who Have Received Multiple Prior Medicines
14-Dec-2009 -
Roche announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of women with advanced (metastatic) HER2-positive breast cancer that had worsened following previous ...
antibody-drug conjugate
breast cancer
chemotherapy
+5